4-Defluoro-4-(p-fluorophenyl)aprepitant-13C, 15N2 |
|
| Synonyms: 4-Defluoro-4-(p-fluorophenyl)aprepitant-13C, 15N2;3-(((2R,3S)-2-((R)-1-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluoro-[1,1-biphenyl]-4-yl)morpholino)methyl)-1H-1,2,4-triazol-5(4H)-one-13C, 15N2 | |
| Cat. No.: A66263 | CAS No.: N.A. |
| MDL.: | Formula: C2813CH25F7N215N2O3 |
| F.W.613.5 | Purity: 99％ |
| Storage: | |
| Size/Unit | Price | Qty | Availability | Price Total |
|---|---|---|---|---|
| 2mg | $250.00 | Enter qty and click checkbox |
 
|
$250.00 |
| Catalog Number： | A66263 | CAS No.: | N.A. | |
| MDL: | Formula: | C2813CH25F7N215N2O3 | ||
| F.W.: | 613.5 | Purity: | 99％ | |
| Package: | Unit: | mg | ||
| Appearance: | M.P.: | |||
| B.P.: | Density: | |||
| Optical Rotation: | Refractive Index: | |||
| Solubility: | Stability: | |||
| Storage: | Category: | Reference Standard | ||
| Reference: | Hale, J.J., et al.: J. Med. Chem., 41, 4607 (1998), Campos, D., et al.: J. Clin. Oncol., 19, 1759 (2001), Van Belle, S., et al.: Cancer, 94, 3032 (2002); Majumdar, A.K., et al.: J. Clin. Pharmacol., 46, 291 (2006) | |||
| Application: | 4-Defluoro-4-(p-fluorophenyl)aprepitant-13C, 15N2 is the labeled analogue of 4-Defluoro-4-(p-fluorophenyl)aprepitant , an impurity of Aprepitant, a novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes indicate that Aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1. Antiemetic. | |||
| Category: | Chiral Reagents, Heterocycles, Impurities, Isotope Labelled Compounds, Pharmaceuticals, Intermediates & Fine Chemicals | |||